Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
CN Bio
CN Bio
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Marketing
CN Bio appoints Joseph Parisi as US Director of Sales
CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), announces the appointment of Joseph Parisi as US Director of Sales
Research & Development
CN Bio wins "Most Impactful Industry Collaboration of the Year" at the OBN Awards
Six-year collaboration recognised at prestigious awards ceremony for its continued success in advancing OOC research to support widespread adoption across the pharmaceutical industry
Research & Development
CN Bio opens new laboratory facilities to extend OOC contract research services capabilities
State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for organ-on-a-chip research services
Research & Development
CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit
Despite research efforts to combat the growing prevalence of NASH, to-date, there are no approved therapeutics
Research & Development
CN Bio and iiCON announce COVID-19 research collaboration
The £174m programme aims to bring together industry, academia, and clinicians to accelerate the discovery, development and deployment of treatments and products
Manufacturing
CN Bio launches oncology service for drug discovery
The service provides a means to explore the relationships between pharmacokinetics, pharmacodynamics (PK/PD) and efficacy in vitro
Research & Development
CN Bio licenses gut modelling tool from MIT
The GuMi device was licensed by Professor Linda Griffith at MIT's Department of Biological Engineering and joint patent-holder, Professor Rebecca Carrier at Northeastern University
Subscribe now